 |
|
dacetuzumab
A humanized monoclonal antibody directed against the CD40 receptor with potential antineoplastic activity. Dacetuzumab specifically binds to and inhibits the CD40 receptor, thereby inducing apoptosis and inhibiting cellular proliferation via antibody-dependent cellular cytotoxicity (ADCC) in cells that overexpress this receptor. The CD40 receptor, a member of the tumor necrosis factor (TNF) receptor super-family, is highly expressed on most B lineage hematologic malignancies including multiple myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's disease and acute lymphoblastic leukemia. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Code name: | | SGN-40 | | | | Chemical structure names: | | - immunoglobulin G1, anti-(human CD40 (antigen)) (human-mouse monoclonal SGN-40 γ1-chain), disulfide with human-mouse monoclonal SGN-40 κ-chain, dimer
- immunoglobulin G1, anti-[human tumor necrosis factor receptor superfamily member 5 (B-cell surface antigen CD40)] humanized mouse monoclonal SGN-40 [Glu353,Met355]γ1 heavy chain (217-219')-disulfide with κ light chain (223-223'':226-226'')-bisdisulfide dimer
| | |
|
|
